Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Rhythm has commenced Phase 2 trial designed to assess the efficacy and safety of RM-493 in obese patients treated for three months.
Subscribe to our email newsletter
The trial will also evaluate the effect of the drug on glucose and insulin resistance.
Rhythm chief development officer Liz Stoner said the Phase 2 study is expected to expand the understanding of RM-493’s profile for the treatment of obesity.
"Based on the data from preclinical studies and early clinical trials, we believe RM-493 has substantial therapeutic potential for reducing body weight and insulin resistance in obese and diabetic patients," Stoner added.
RM-493 is a small-peptide melanocortin 4 receptor (MC4R) agonist that is being developed for the treatment of obesity and diabetes.